The company’s share price has soared since the beginning of the Covid-19 pandemic thanks to its development of a preventative vaccine, which helped lift sales and revenues to record levels. AstraZeneca expects revenues to remain strong if demand for its products remains high, although it has warned that the Covid-19 boost could fade over time.